A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

NCT ID: NCT01724177

Last Updated: 2018-05-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-11-12
• Study Completion Date: 2017-03-21

Brief Summary

To evaluate the efficacy of lenalidomide in patients with Adult T-cell Leukemia-lymphoma (ATL) who have previously received chemotherapy for ATL.

Conditions

Adult T-Cell Leukemia-Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Lenalidomide

Lenalidomide 25mg by mouth (PO) daily until progressive disease or unacceptable toxicity

Group Type: EXPERIMENTAL

Lenalidomide

Intervention Type: DRUG

25 mg of Lenalidomide administered orally once daily

Interventions

Lenalidomide

25 mg of Lenalidomide administered orally once daily

Intervention Type: DRUG

Other Intervention Names

Revlimid

Eligibility Criteria

Inclusion Criteria

• Must understand and voluntarily sign the informed consent
• Aged 20 years or older (at the time of signing the informed consent)
• Have a documented diagnosis of either: acute-, lymphoma-, or unfavorable chronic-type adult T-cell leukemia-lymphoma
• Have received ≥1 prior anti-adult T-cell leukemia-lymphoma therapy, have achieved stable disease or better on their immediately prior therapy and have relapsed or progressed at the time of obtaining signed informed consent
• Subjects for whom at least 1 measurable lesion (measurable lesion of computed tomography scan, peripheral blood or skin lesion) is confirmed in the lesion assessment before registration
• Have an Eastern Cooperative Oncology Group performance status of 0 to 2 at registration
• Must be able to adhere to the study visit schedule and other protocol requirements
• Must agree to comply to Lenalidomide Pregnancy Prevention Risk Management Plan

Exclusion Criteria

• Have a history of central nervous system involvement or present with central nervous system symptoms, and are diagnosed with central nervous system lymphoma by cerebrospinal fluid cytology examination, head computed tomography scan or brain magnetic resonance imaging during the screening
• Are pregnant or lactating
• Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. Examples of such medical condition are, but are not limited to, as follows:

• Uncontrolled diabetes mellitus as defined by the investigator or sub-investigator
• Chronic congestive heart failure (New York Heart Association Class III or IV)
• Unstable angina pectoris, angioplasty, stenting, or myocardial infarction (within 6 months before starting the study drug)
• Clinically significant cardiac arrhythmia that is symptomatic or requires treatment, or asymptomatic sustained ventricular tachycardia (subjects with controlled atrial fibrillation that is asymptomatic are eligible for this study)
• Major surgery within 28 days of the start of study treatment
• Exhibit grade 4 neurological disorders
• Patients who are at a high risk for a thromboembolic event and are not willing to take venous thromboembolic prophylaxis.
• Develop active tuberculous disease, herpes simplex, systemic mycosis, or other active infections requiring systemic administration of antibiotics, antiviral agents, or antifungal drugs
• Known human immunodeficiency virus positivity
• Have hepatitis B surface antigen-positive, or hepatitis C virus anti-body positive. In case hepatitis B core antibody and/or hepatitis B surface antibody is positive even if hepatitis B surface antigen-negative, a hepatitis B virus deoxyribonucleic acid test should be performed and if positive the subject will be excluded
• Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
• Have a history of allogenic stem cell transplantation
• Have received autologous stem cell transplantation within 12 weeks (84 days) of the start of study treatment
• Have previously used lenalidomide
• Have a history of desquamating (blistering) rash while taking thalidomide
• Have received any investigational drugs (unapproved drugs in Japan) within 4 weeks (28 days) of the start of study medication
• Have received any antibody agents within 12 weeks (84 days) of the start of study medication
• Have received chemotherapeutic agents or immunomodulatory drugs for the treatment of adult T-cell leukemia-lymphoma within 4 weeks (28 days) of the start of study treatment
• Have received radiotherapy within 4 weeks (28 days) of the start of study treatment
• Have a history or complication of another malignant tumor other than adult T-cell leukemia-lymphoma and the following malignant tumors, unless the patients have been free of the disease for 5 years or longer

• Basal cell carcinoma of the skin
• Squamous cell carcinoma of the skin
• Cervical carcinoma in situ
• Carcinoma in situ of the breast
• An incidental histological finding of prostate carcinoma (TNM stage T1a or T1b)
• Early-stage gastric cancer treated with endoscopic mucosal resection or endoscopic submucosal dissection
• Have had any of the following abnormal measurements at screening performed within 1 week (7 days) prior to the registration;

• Neutrophil count: < 1,200/µL
• Platelet count: < 75,000/µL
• Serum aspartate aminotransferase/glutamyl oxaloacetic transaminase or alanine aminotransferase/glutamyl pyruvic transaminase: > 3 times the upper limit of normal
• Bilirubin level: > 1.5 times the upper limit of normal
• Creatinine clearance: < 60 mL/min
• Any condition that confounds the ability to interpret data from the study.

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Celgene

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Toru Sasaki

Role: STUDY_DIRECTOR

Celgene K.K.

Locations

Nagoya City University Hospital

Nagoya, Aichi-ken, Japan

National Cancer Center Hospital East

Kashiwa, Chiba, Japan

Ehime University Hospital

Tōon, Ehime, Japan

Iwate Medical University Hospital

Morioka, Iwate, Japan

Tohoku University Hospital

Sendai, Miyagi, Japan

Sasebo City General Hospital

Sasebo, Nagasaki, Japan

Heart Life Hospital

Nakagami, Okinawa, Japan

Shimane University Hospital

Izumo, Shimane, Japan

National Hospital Organization Kyushu Cancer Center

Fukuoka, , Japan

Kyushu University Hospital

Fukuoka, , Japan

Imamura Bunin Hospital

Kagoshima, , Japan

Kagoshima University Medical and Dental Hospital

Kagoshima, , Japan

National Hospital Organization Kagoshima Medical Center

Kagoshima, , Japan

Kumamoto University Hospital

Kumamoto, , Japan

Nagasaki University Hospital

Nagasaki, , Japan

The Japanese Red Cross Nagasaki Genbaku Hospital

Nagasaki, , Japan

Oita Prefectual Hospital

Ōita, , Japan

National Cancer Center Hospital

Tokyo, , Japan

Countries

Japan

References

Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, Moriuchi Y, Jo T, Ishizawa K, Tobinai K, Tsukasaki K, Ito S, Yoshimitsu M, Otsuka M, Ogura M, Midorikawa S, Ruiz W, Ohtsu T. Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. J Clin Oncol. 2016 Dec;34(34):4086-4093. doi: 10.1200/JCO.2016.67.7732. Epub 2016 Sep 30.

Reference Type: RESULT

PMID: 27621400 (View on PubMed)

Other Identifiers

CC-5013-ATLL-002

Identifier Type: -

Identifier Source: org_study_id